Bristol-Myers Squibb Company
Price Action
Technical Summary
STAGE 2 UPTRENDBristol-Myers Squibb Company is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 80% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $59.87 | +4.18% | ABOVE |
| 50 SMA | $56.82 | +9.77% | ABOVE |
| 100 SMA | $51.95 | +20.07% | ABOVE |
| 150 SMA | $50.07 | +24.55% | ABOVE |
| 200 SMA | $49.45 | +26.13% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BMY in an uptrend right now?
BMY has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BMY is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BMY overbought or oversold?
BMY's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is BMY outperforming the market?
BMY has a Relative Strength (RS) Rating of 80 out of 99. Yes, BMY is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is BMY in its 52-week range?
BMY is trading at $62.37, which is 98% of its 52-week high ($63.33) and 95% above its 52-week low ($42.52).
How volatile is BMY?
BMY has a Beta of 0.35 and 52-week volatility of 29%. It's less volatile than the S&P 500 - generally more stable.